Different molecule, different approvals, same weekly shot. Here's what the head-to-head trial actually found — weight loss, side effects, approvals, cost.
In the SURMOUNT-5 head-to-head trial, Zepbound (tirzepatide) produced 20.2% average weight loss at 72 weeks, versus 13.7% for Wegovy (semaglutide). But Wegovy carries FDA approvals Zepbound doesn't — cardiovascular risk reduction and MASH — and now comes as a pill too.
Per SURMOUNT-5 head-to-head trial results, Eli Lilly. Not medical advice — individual response varies; talk to your prescriber before switching.
Per official prescribing information and manufacturer pricing pages · not medical advice — confirm current pricing with your prescriber and pharmacy
SURMOUNT-5 was the first head-to-head trial directly comparing tirzepatide (Zepbound) and semaglutide (Wegovy) for weight management. Zepbound produced greater average weight loss, but also more frequent GI side effects. Individual results vary.
Wegovy has an FDA approval specifically for reducing cardiovascular risk — Zepbound doesn't yet.
Zepbound has an FDA approval for moderate-to-severe obstructive sleep apnea — Wegovy doesn't.
Wegovy now comes as an oral pill (25mg). No FDA-approved tirzepatide pill exists yet.
Zepbound showed a larger average weight loss in the head-to-head trial, though results vary by person.
Wegovy had a lower rate of nausea and vomiting than Zepbound in the head-to-head trial.
Switching is a conversation for your prescriber, not a decision to make solo.
One email at launch · free trial · no credit card